Filing Details

Accession Number:
0001235802-23-000030
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-07 16:11:11
Reporting Period:
2023-01-24
Accepted Time:
2023-03-07 16:11:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1427570 Reshape Lifesciences Inc. RSLS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181166 Thomas Stankovich 1001 Calle Amanecer
San Clemente CA 92673
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Disposition 2023-01-24 48 $7.49 6,461 No 4 S Direct
Common Stock, $0.001 Par Value Per Share Disposition 2023-01-24 110 $7.49 6,351 No 4 S Direct
Common Stock, $0.001 Par Value Per Share Disposition 2023-02-02 157 $13.29 6,194 No 4 S Direct
Common Stock, $0.001 Par Value Per Share Disposition 2023-02-28 103 $4.25 6,091 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
  2. On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.